AR031250A1 - COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CANCER DE PULMON - Google Patents

COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CANCER DE PULMON

Info

Publication number
AR031250A1
AR031250A1 ARP010103274A ARP010103274A AR031250A1 AR 031250 A1 AR031250 A1 AR 031250A1 AR P010103274 A ARP010103274 A AR P010103274A AR P010103274 A ARP010103274 A AR P010103274A AR 031250 A1 AR031250 A1 AR 031250A1
Authority
AR
Argentina
Prior art keywords
compositions
diagnosis
cancer
polypeptides
therapy
Prior art date
Application number
ARP010103274A
Other languages
Spanish (es)
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/614,124 external-priority patent/US6630574B1/en
Priority claimed from US09/651,563 external-priority patent/US6914132B1/en
Priority claimed from US09/658,824 external-priority patent/US6746846B1/en
Priority claimed from US09/671,325 external-priority patent/US6667154B1/en
Priority claimed from US09/702,705 external-priority patent/US6504010B1/en
Priority claimed from US09/736,457 external-priority patent/US6509448B2/en
Priority claimed from US09/849,626 external-priority patent/US20020197669A1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AR031250A1 publication Critical patent/AR031250A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Composiciones y métodos para la terapia y el diagnostico del cáncer, particularmente, el cáncer de pulmon. Composiciones ilustrativas comprenden uno o más polipéptidos de tumor de pulmon, porciones inmunogénicas de los mismos, polinucleotidos que codifican dichos polipéptidos, células que presentan antígenos que expresan dichos polipéptidos, y células T que son específicas de las células que expresan dichos polipéptidos. Las composiciones son utiles, por ejemplo, en el diagnostico, prevencion y/o tratamiento de enfermedades, particularmente de cáncer de pulmon.Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides encoding said polypeptides, cells presenting antigens that express said polypeptides, and T cells that are specific to cells expressing said polypeptides. The compositions are useful, for example, in the diagnosis, prevention and / or treatment of diseases, particularly lung cancer.

ARP010103274A 2000-07-11 2001-07-10 COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CANCER DE PULMON AR031250A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US09/614,124 US6630574B1 (en) 1999-06-30 2000-07-11 Compositions and methods for the therapy and diagnosis of lung cancer
US09/651,563 US6914132B1 (en) 1999-06-30 2000-08-29 Compositions and methods for the therapy and diagnosis of lung cancer
US09/658,824 US6746846B1 (en) 1999-06-30 2000-09-08 Methods for diagnosing lung cancer
US09/671,325 US6667154B1 (en) 1999-06-30 2000-09-26 Compositions and methods for the therapy and diagnosis of lung cancer
US67741900A 2000-10-06 2000-10-06
US09/702,705 US6504010B1 (en) 1999-06-30 2000-10-30 Compositions and methods for the therapy and diagnosis of lung cancer
US09/736,457 US6509448B2 (en) 1999-06-30 2000-12-13 Compositions and methods for the therapy and diagnosis of lung cancer
US09/849,626 US20020197669A1 (en) 2000-12-13 2001-05-03 Compositions and methods for the therapy and diagnosis of lung cancer

Publications (1)

Publication Number Publication Date
AR031250A1 true AR031250A1 (en) 2003-09-17

Family

ID=27575493

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103274A AR031250A1 (en) 2000-07-11 2001-07-10 COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CANCER DE PULMON

Country Status (6)

Country Link
EP (1) EP1343886A2 (en)
JP (1) JP2004512824A (en)
AR (1) AR031250A1 (en)
AU (1) AU2002218770A1 (en)
CA (1) CA2415544A1 (en)
WO (1) WO2002004514A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030170255A1 (en) * 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
CA2494705A1 (en) * 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030166300A1 (en) * 2000-08-30 2003-09-04 Tang Y. Tom Growth-related inflammatory and immune response protein
ZA200204907B (en) 2001-06-26 2003-03-03 Univ Nat Taiwan Collapsin Response Mediator Protein-1.
JP2006512056A (en) * 2002-08-14 2006-04-13 エルジー・ライフ・サイエンシーズ・リミテッド Liver cancer-related gene family
US20060258574A1 (en) * 2002-09-26 2006-11-16 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US7449291B1 (en) 2003-01-13 2008-11-11 University Of Washington Methods for identifying subjects susceptible to Charcot-Marie-Tooth neuropathy type 1C
WO2004070058A1 (en) * 2003-02-03 2004-08-19 Bayer Healthcare Ag Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of copd
US20070042368A1 (en) * 2003-03-24 2007-02-22 Corixa Corporation Detection and monitoring of lung cancer
ATE528397T1 (en) 2003-08-08 2011-10-15 Perseus Proteomics Inc GENE OVEREXPRESSED IN CANCER
TW200512298A (en) * 2003-09-24 2005-04-01 Oncotherapy Science Inc Method of diagnosing breast cancer
JP4428995B2 (en) 2003-12-03 2010-03-10 関東化学株式会社 Etching solution composition for metal film
WO2006131783A2 (en) * 2004-01-27 2006-12-14 Compugen Usa, Inc. Polynucleotides, polypeptides, and diagnosing lung cancer
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP1744162B1 (en) 2004-03-31 2010-08-04 Hiroyuki Aburatani Cancer diagnosis and treatment using anti-robo1 antibody
US8940488B2 (en) 2004-03-31 2015-01-27 Hiroyuki Aburatani Cancer diagnosis and treatment of cancer using anti-robo 1 antibody
US7943295B2 (en) * 2005-07-29 2011-05-17 Oncotherapy Science, Inc. Screening and therapeutic method for NSCLC targeting CDCA1-KNTC2 complex
CN101583715A (en) * 2006-12-21 2009-11-18 因特拉迪格姆公司 Inhibitory polynucleotide compositions and methods for treating cancer
JP5117765B2 (en) 2007-05-28 2013-01-16 国立大学法人 東京大学 Tumor diagnostic agent for PET containing anti-ROBO1 antibody
AU2008290061B2 (en) 2007-08-20 2014-01-30 Oncotherapy Science, Inc. CDCA1 peptide and pharmaceutical agent comprising the same
TWI526219B (en) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1 epitope peptides and vaccines containing the same
US20120064102A1 (en) * 2009-05-22 2012-03-15 National University Corporation Okayama University Peptide inducing xage-1b-specific immune reaction and utilization of same
WO2014010229A1 (en) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Cdca1 epitope peptides for th1 cells and vaccines containing the same
CN114102955A (en) * 2020-08-31 2022-03-01 天津科技大学 Method for preparing foamed polylactic acid by adopting normal-temperature foaming technology

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10139800A (en) * 1996-11-15 1998-05-26 Santen Pharmaceut Co Ltd Therapeutic agent for sjogren's syndrome
ID27813A (en) * 1998-01-28 2001-04-26 Corixa Corp COMPOUNDS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER AND METHODS FOR USE
AU3899700A (en) * 1999-03-17 2000-10-04 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
BR0012069A (en) * 1999-06-30 2002-08-27 Corixa Corp Compositions and methods for therapy and diagnosis of lung cancer

Also Published As

Publication number Publication date
CA2415544A1 (en) 2002-01-17
WO2002004514A2 (en) 2002-01-17
EP1343886A2 (en) 2003-09-17
WO2002004514A3 (en) 2003-06-19
JP2004512824A (en) 2004-04-30
AU2002218770A1 (en) 2002-01-21
WO2002004514A8 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
AR031250A1 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CANCER DE PULMON
AR032743A1 (en) COMPOSITIONS AND METHODS FOR CANCER DE PULMON THERAPY AND DIAGNOSIS
MXPA03001634A (en) Vaccines.
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
BR0009537A (en) Compositions for treatment and diagnosis of breast cancer and methods for its use
WO2001092581A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
HK1083866A1 (en) Hla-a24-restricted cancer antigen peptides hla-a24
MXPA03001389A (en) Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies.
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
BR9808509A (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2006031363A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
HRPK20041072B3 (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
WO2003037267A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
DE602004020266D1 (en) THERAPEUTIC AND DIAGNOSTIC ANTI-HSP 70 ANTIBODIES
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
MXPA02011563A (en) Compositions and methods for the therapy and diagnosis of breast cancer.
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2005051990A3 (en) Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer
AR029547A1 (en) COMPOSITIONS AND METHODS FOR CANCER DE PULMON THERAPY AND DIAGNOSIS
WO2002000174A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003086175A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
ATE435284T1 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER
DE60326931D1 (en) DIFFERENTIALLY EXPRESSED GENEVA PRODUCTS AND THEIR USE PROCEDURES IN CANNULAR MAMMA CELLS
WO2002062203A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
BRPI0409321A (en) antigen hybrid, competition and method for inducing an immune response to an infectious agent or tumor antigen, method for treating an infectious disease or cancer, and, peptide

Legal Events

Date Code Title Description
FB Suspension of granting procedure